Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Melanoma 6Squamous Cell Carcinoma of Head and Neck 4Head and Neck Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Breast Neoplasms 4Triple Negative Breast Neoplasms 3Sarcoma 3Neoplasms 3Endometrial Neoplasms 3Neoplasm Metastasis 2Lymphoma 2Leukemia, Myeloid, Acute 2Carcinoma, Hepatocellular 2Uterine Neoplasms 1Smoldering Multiple Myeloma 1Skin Neoplasms 1SCLC 1Recurrence 1Pathologic Complete Response 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Myelodysplastic Syndromes 1Muscle Invasive Bladder Urothelial Carcinoma 1Motor Activity 1Lymphoma, B-Cell 1Lung Neoplasms 1Hodgkin Disease 1Glioma 1Genital Neoplasms, Female 1Fallopian Tube Neoplasms 1

Interventions

pembrolizumab 1gadoterate meglumine 1Mifepristone 1Mastectomy, Simple 1Ferric Oxide, Saccharated 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Carcinoma, Intraductal, Noninfiltrating × pembrolizumab × Clear all
NCT02872025 2025-01-30

Immunotherapy in High-risk Ductal Carcinoma in Situ (DCIS)

University of California, San Francisco

Phase EARLY_PHASE1 Active not recruiting
42 enrolled
Breast

Carcinoma, Intraductal, Noninfiltrating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡